RXi Pharmaceuticals Announces Upcoming Presentations AsiaTIDES 25th Annual ROTH Conference Business Wire WESTBOROUGH, Mass. -- February 19, 2013 RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced upcoming presentations at AsiaTIDES and at the ROTH 25th Annual Conference. AsiaTIDES On Tuesday, February 26, 2013 at 9:40 am JST, Karen G. Bulock, Ph.D., Vice President of Research for RXi Pharmaceuticals will be participating in a Tutorial Session on approaches to Successful Delivery of Oligonucleotides in vivo, where she will discuss “Local Delivery: Lessons Learned from 'Self-Delivering' RNAi Compounds”. Dr. Bulock’s presentation will be available on the Company's website. On February 27, 2013 at 1:40 pm JST, RXi’s Chief Development Officer, Pamela A. Pavco, Ph.D., will be presenting an update on RXI-109, an RNAi Compound in Clinical Development to Reduce Dermal Scarring. RXI-109 is the first member of a novel class of RNAi compounds, termed 'self-delivering' or sd-rxRNA, to enter into clinical development. RXI-109 targets connective tissue growth factor (CTGF), a key regulator of fibrosis and scar formation, and is initially being developed to reduce or inhibit dermal scarring. Dr. Pavco’s presentation will be available on the Company's website. This conference is being held February 26-28, 2013 at the Sheraton Miyako Hotel, Tokyo, Japan. For more information visit: http://www.ibclifesciences.com/AsiaTIDES ROTH 25^th Annual Conference The Company’s President and Chief Executive Officer, Dr. Geert Cauwenbergh, will present at the ROTH 25^th Annual Conference on Tuesday, March 19, 2013 at 1:30 pm PT. Dr. Cauwenbergh will discuss the development of RXI-109, a self-delivering RNAi compound designed to reduce dermal scarring, as well as business development opportunities with RXi’s sd-rxRNA® technology platform. A live webcast of the presentation will be available on the “Investors” section of the Company's website, www.rxipharma.com. A replay of the presentation will be available for 90 days. This conference is being held March 17-20, 2013at the Ritz-Carlton Laguna Niguel in Dana Point, CA. For more information visit: http://www.roth.com. To schedule a meeting with RXi Pharmaceuticals at this conference, please submit your request to email@example.com. The deadline is March 1, 2013 for requests. About RXi Pharmaceuticals Corporation RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, self-delivering RNAi platform. Therapeutics that use RNA interference, or “RNAi,” have great promise because of their ability to down-regulate the expression of a specific gene that may be over-expressed in a disease condition. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board, RXi’s first RNAi product candidate, RXI-109, which targets CTGF, entered into human clinical development in June 2012. For more information, please visit www.rxipharma.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, planned and future development of RXi Pharmaceuticals Corporation’s products and technologies. Forward-looking statements about expectations and development plans of RXi’s products involve significant risks, and uncertainties: risks that RXi may not be able to successfully develop its candidates, or that development of RNAi-based therapeutics may be delayed or not proceed as planned, or that we may not develop any RNAi-based product; risks that the development process for our product candidates may be delayed, risks related to development and commercialization of products by our competitors, risks related to our ability to control timing and terms of collaborations with third parties, and the possibility that other companies or organizations may assert patent rights preventing us from developing our products. Actual results may differ from those contemplated by these forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release. Contact: RXi Pharmaceuticals Corporation Tamara McGrillen, 508-929-3646 firstname.lastname@example.org
RXi Pharmaceuticals Announces Upcoming Presentations
Press spacebar to pause and continue. Press esc to stop.